Jean Franchi Sells 6,257 Shares of Disc Medicine (NASDAQ:IRON) Stock

Key Points

• CFO Jean Franchi sold 6,257 shares of Disc Medicine on April 14 at an average price of $69.24 for a total of $433,234.68, leaving him with 64,333 shares — an 8.86% reduction in his stake.
• Shares traded down about 0.4% to $70.18 midday with 300,163 shares exchanging hands (vs. average volume 660,190); the stock has a 52‑week range of $39.20–$99.50, a market cap of $2.68B and a negative P/E of -11.72.
• Large institutions have been buying — including RA Capital, Vanguard, Price T. Rowe and JPMorgan — leaving roughly 83.7% institutional ownership, and analysts hold a consensus "Moderate Buy" with a $104.80 target price.

Disc Medicine, Inc. (NASDAQ:IRON - Get Free Report) CFO Jean Franchi sold 6,257 shares of the firm's stock in a transaction on Tuesday, April 14th. The stock was sold at an average price of $69.24, for a total value of $433,234.68. Following the transaction, the chief financial officer owned 64,333 shares of the company's stock, valued at approximately $4,454,416.92. This represents a 8.86% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Disc Medicine Trading Down 0.4%

Shares of IRON traded down $0.30 during midday trading on Wednesday, hitting $70.18. 300,163 shares of the stock were exchanged, compared to its average volume of 660,190. Disc Medicine, Inc. has a 52-week low of $39.20 and a 52-week high of $99.50. The stock has a fifty day simple moving average of $64.99 and a 200 day simple moving average of $76.18. The firm has a market cap of $2.68 billion, a P/E ratio of -11.72 and a beta of 0.91. The company has a debt-to-equity ratio of 0.04, a quick ratio of 21.94 and a current ratio of 21.94.

Disc Medicine (NASDAQ:IRON - Get Free Report) last released its quarterly earnings results on Thursday, February 26th. The company reported ($1.62) EPS for the quarter, topping the consensus estimate of ($1.69) by $0.07. The firm had revenue of ($19.88) million for the quarter, compared to analysts' expectations of $0.15 million. On average, research analysts anticipate that Disc Medicine, Inc. will post -4.07 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. RA Capital Management L.P. boosted its holdings in Disc Medicine by 25.3% in the fourth quarter. RA Capital Management L.P. now owns 1,976,132 shares of the company's stock valued at $156,925,000 after purchasing an additional 399,026 shares during the period. Vanguard Group Inc. raised its stake in Disc Medicine by 22.1% in the fourth quarter. Vanguard Group Inc. now owns 1,767,680 shares of the company's stock valued at $140,371,000 after buying an additional 319,621 shares in the last quarter. Price T Rowe Associates Inc. MD raised its stake in Disc Medicine by 28.0% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,698,005 shares of the company's stock valued at $134,839,000 after buying an additional 371,576 shares in the last quarter. JPMorgan Chase & Co. boosted its position in shares of Disc Medicine by 110.0% during the 4th quarter. JPMorgan Chase & Co. now owns 1,581,127 shares of the company's stock worth $125,557,000 after acquiring an additional 828,248 shares in the last quarter. Finally, Wellington Management Group LLP increased its holdings in shares of Disc Medicine by 7.7% in the 4th quarter. Wellington Management Group LLP now owns 1,518,274 shares of the company's stock valued at $120,566,000 after acquiring an additional 108,197 shares during the last quarter. 83.70% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

IRON has been the subject of several research analyst reports. UBS Group restated an "overweight" rating on shares of Disc Medicine in a research report on Thursday, January 15th. Truist Financial lowered their price target on Disc Medicine from $114.00 to $83.00 and set a "buy" rating for the company in a research report on Friday, February 27th. Raymond James Financial reiterated a "market perform" rating on shares of Disc Medicine in a report on Thursday, January 15th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Disc Medicine in a report on Wednesday, January 21st. Finally, Wedbush decreased their target price on Disc Medicine from $110.00 to $88.00 and set an "outperform" rating for the company in a report on Tuesday, February 17th. Ten research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $104.80.

About Disc Medicine

Disc Medicine, Inc NASDAQ: IRON is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company's pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.